

REFERENCES:

- **Brownlee, M.** et al. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. *Annals of Internal Medicine* 1984 101, 527-537.
- **V. Monnier**, V Vishwanath, K.E. Frank, C.A. Elmets, P. Dauchot, and R.R. Kohn, "Relation between complications of Type I diabetes mellitus and collagen-linked fluorescence," *NEJM* 314:403-8 (1986).
- **V. Monnier** et al., "Age-related Normalization of the Browning Rate of Collagen in Diabetic Subjects Without Retinopathy," *J Clin Invest* 78:832-835 (1986).
- **B. Buckingham** and K.M. Reiser, "Relationship between the Content of Lysyl Oxidase-dependent Crosslinks in Skin Collagen, Nonenzymatic Glycosylation, and Long-Term Complications in Type I Diabetes Mellitus," *J Clin Invest*, 86:1046-1054 (1990).
- **D.R. Sell**, A. Lapolla, P. Odetti, and V.M. Monnier, "Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM," *Diabetes* 41:1286-92 (1992).
- **R. McCance**, D.G. Dyer, J.A. Dunn, K.E. Bailie, S.R. Thorpe, J.U.W. Baynes, and T.J. Lyons, "Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus," *J Clin Invest* 91:2470-2478 (1993).
- **Vlassara H**, Striker LJ, Teichberg S et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. *Proc Natl Acad Sci USA* 1994; 91: 11704-8.
- **Hammes HP**, Strodtter D, Weiss A et al. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. *Diabetologia* 1995; 38: 656-60.
- **Beisswenger PJ**, Makita Z, Curphey TJ et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. *Diabetes* 1995; 44: 824-9.
- **Soulis T**, Cooper ME, Sastra S et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. *Diabetologia* 1997; 40: 1141-51.
- **Booth A.** et al. (1997) *In vitro* kinetic studies of formation of antigenic advanced glycation end products (AGEs). *Journal of Biological Chemistry* 272, 5430-5437.
- **Sajithlal, G.** et al. (1998) Advanced glycation end products induce crosslinking of collagen in vitro. *Biochimica et biophysica Acta* 1407, 215-224.
- **Degenhardt, T.** et al. (1999) Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. *Diabetes research and clinical practice* 43, 81-89.
- **Baynes J.** et al. (1999) Role of oxidative stress in diabetic complications. *Diabetes* 48, 1-9.
- **V.M. Monnier**, O. Bautista, D. Kenny, D.R. Sell, J. Fogarty, W. Daahms, P.A. Cleary, J. Lachin, S. Genuth, and the DCCT Skin Collagen Ancillary Study Group, "Skin collagen glycation, glycooxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes," *Diabetes* 48: 870-880 (1999).

- **Ulrich, P** and Cerami A. (2001) Protein glycation, diabetes and aging. *Recent Progress in Hormone Research* 56, 1-22.
- **Wautier, J.L.** and Guillausseau, P.J (2001) Advanced glycation end products, their receptors and diabetic angiopathy. *Diabetes Metabolism* 27, 535-542.
- **Hartog J.** et al., Advanced glycation endproducts in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction *Am J Kidn Dis* 2004; 43:966-975
- **Meerwaldt R** et al., Simple non-invasive assessment of advanced glycation endproducts accumulation. *Diabetologia* 2004; 47:1324-1330
- **Smit AJ**, Lutgers HL., The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceuticals to reduce AGE accumulation. *Curr Med Chem.* 2004 Oct; 11(20):2767-84.
- **Ahmed N** (2005) Advanced glycation endproducts – role in pathology of diabetic complications. *Diabetes Research and Clinical Practice* 67, 3-21.
- **Meerwaldt R**, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ: Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. *Diabetologia* 48:1637– 1644, 2005
- **Genuth S**, Sun W, Cleary P, et al for the DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. *Diabetes.* 2005; 54:3103-3111.
- **Mulder DJ**, Water TV, Lutgers HL, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. *Diabetes Technol Ther.* 2006; 8:523-535.
- **Lutgers H**, et al., Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. *Diabetes Care.* 2006 Dec;29(12):2654-9
- **Ahmed N, Thornalley PJ** (2006): Advanced glycation endproducts: what is their relevance to diabetic complications?. *Diabetes, Obesity and Metabolism.* 10.1111/j.1463-1326.2006.00595.x,
- **Goldin A**, Beckman JA, Schmidt AM, Creager MA (2006): Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury. *Circulation.* 114:597-605.
- **Meerwaldt R**, et al., Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. *Diabetes Care* 2007, 30: 107-112
- **Lapolla A**, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D (2007): Advanced Glycation End Products and Antioxidant Status in Type 2 Diabetic Patients With and Without Peripheral Artery Disease. *Diabetes Care.* 30:670-676.
- **den Hollander NC**, et al. ,Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia. *J Inherit Metab Dis.* 2007 Jun 14

- **Mulder DJ.** et al., Skin Autofluorescence is a Non-invasive Marker for Inflammatory Stress in Stable Coronary Artery Disease Atherosclerosis 2007, in press.
- **Mulder DJ,** et al., The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress. *Cardiovasc Drugs Ther.* 2007 Apr; 21(2):91-7.